1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Acute Heart Failure-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Acute Heart Failure-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Acute Heart Failure. This report provides information on the therapeutic development based on the Acute Heart Failure dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Acute Heart Failure pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Acute Heart Failure and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Acute Heart Failure
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Acute Heart Failure-Pipeline Insights, 2014
Table of Contents
- Acute Heart Failure Overview
- Acute Heart Failure Pipeline Therapeutics
- Acute Heart Failure Therapeutics under Development by Companies
- Acute Heart Failure Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Acute Heart Failure Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Acute Heart Failure Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Acute Heart Failure Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Acute Heart Failure - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Acute Heart Failure - Discontinued Products
- Acute Heart Failure - Dormant Products
- Companies Involved in Therapeutics Development for Acute Heart Failure
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Acute Heart Failure, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Acute Heart Failure Assessment by Monotherapy Products
- Acute Heart Failure Assessment by Combination Products
- Acute Heart Failure Assessment by Route of Administration
- Acute Heart Failure Assessment by Stage and Route of Administration
- Acute Heart Failure Assessment by Molecule Type
- Acute Heart Failure Assessment by Stage and Molecule Type
- Acute Heart Failure Therapeutics - Discontinued Products
- Acute Heart Failure Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Acute Heart Failure, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Acute Heart Failure Assessment by Monotherapy Products
- Acute Heart Failure Assessment by Combination Products
- Acute Heart Failure Assessment by Route of Administration
- Acute Heart Failure Assessment by Stage and Route of Administration
- Acute Heart Failure Assessment by Molecule Type
- Acute Heart Failure Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Acute heart failure (AHF) - Epidemiology Forecast To 2023

Acute heart failure (AHF) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Acute heart failure (AHF) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Acute heart failure (AHF) in seven major markets (US, France, Germany, Italy, ...

Chronic Heart Failure - Epidemiology Forecast To 2023

Chronic Heart Failure - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Chronic Heart Failure - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Chronic Heart Failure in seven major markets (US, France, Germany, Italy, Spain, ...

Diastolic Heart Failure Global Clinical Trials Review, H2, 2016

Diastolic Heart Failure Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by Global Data

Diastolic Heart Failure Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Diastolic Heart Failure Global Clinical Trials Review, H2, 2016" provides an overview of Diastolic ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.